PM Group Announces Project Wins with Novartis in Singapore

PM Group Announces Project Wins with Novartis in Singapore

Singapore, 11 February 2014 - PM Group has announced that it has been awarded a contract for two expansion projects in Singapore. The projects are part of on-going site improvements at the Novartis facility in Tuas Biomedical Park, Singapore.

Included is a production facility expansion where PM Group will provide engineering, procurement and construction management services and the development of a new GMP warehouse and a raw material laboratory where the company will provide design, project management and construction management support services.

The announcement was made at a contract signing during the recent Trade Mission to Singapore by the Irish Minister for Jobs, Enterprise and Innovation, Mr Richard Bruton T.D.

Participating in the signing event was Pat Ryan, Operations Manager for PM Group in Singapore and Samuel Williamson, GPE Asia Lead for Novartis.

Speaking on the trade mission, Minister Bruton said: "Irish construction and engineering firms have showed over recent years an extraordinary ability to diversify into international markets and win major contracts with leading international companies. Today's announcement by PM Group that it has won a significant contract with Novartis to provide specialist services on its plant in Tuas Biomedical Park in Singapore is a major achievement".

Since establishing its Asia operations in Singapore in 2007, International engineering design and project management firm PM Group has gone on to open offices in Bangalore, India and Shanghai, China. Within the ASEAN region, PM Group's multi-disciplinary team works on projects throughout Singapore, Malaysia, Indonesia, Vietnam and Thailand. The company offers international expertise coupled with local knowledge and capability to successfully deliver projects to their multinational clients.

Commenting on PM Group's commitment to the ASEAN market, Pat Ryan noted:

"PM Group has seen activity levels across Asia increase significantly in recent years and these projects for Novartis are examples of the type of work we're winning. We have a well established track record of consistently delivering a high level of service to our clients across different markets and our ability to provide design excellence, safety and quality consistently has resulted in a lot of repeat business from key clients such as Novartis. This contract is for a key process expansion project within the Novartis Group globally and PM Group was selected to provide these services due to our process design expertise and project delivery experience".

In Singapore, PM Group is currently working on Life Science and Food sector projects across the ASEAN region for clients including Abbott, Amgen, Roche, Merck and Novartis amongst others.

- ends -

For further information, please contact:

Megan Yulga, Marketing & Business Development Executive, PM Group

T: +65 6643 5731 M: +65 9456 3498

e: [email protected];

Niamh Milne, Group Marketing Manager, PM Group

T: +353 1 404 0724 M: +353 87 646 8913

e: [email protected];

About PM Group

International professional services firm, PM Group, is celebrating its 40th year in business. The company has a unique track record in the engineering, design and project management of complex projects for clients across the pharmaceutical, food, ICT, advanced manufacturing, medical technologies and energy sectors.

Established in 1973, PM Group has over 2,000 people across a network of 20 offices in Europe, Asia, UK and the US, providing clients with a comprehensive portfolio of services ranging from small consultancy studies to large-scale, capital projects globally.

www.pmgroup-global.com

Suggested Articles

Reblozyl, a key drug in Bristol Myers Squibb's Celgene merger, has won a key FDA nod to treat patients with myelodysplastic syndromes.

Wealthy individuals typically don't set out to waste billions of dollars, but amid the COVID-19 pandemic, that’s exactly what Bill Gates plans to do.

GSK's Nucala is hoping to parlay positive phase 3 data in nasal polyps into a first-of-its-kind approval for the IL-5 class.